MAPK14 and rheumatoid arthritis: Dilmapimod (67, CAS 444606-18-2) is a p38 MAP-kinase inhibitor with potential uses in rheumatoid arthritis that was patented by SmithKline Beecham Corporation (GSK-681323) in 2001 [113] and has been involved in clinical trials for inflammation, neuropathic pain, and heart diseases but was finally discontinued due to liver toxicity.